2019
DOI: 10.1074/jbc.ra119.010007
|View full text |Cite
|
Sign up to set email alerts
|

Xenogeneic modulation of the ClpCP protease of Bacillus subtilis by a phage-encoded adaptor-like protein

Abstract: Like eukaryotic and archaeal viruses, which coopt the host's cellular pathways for their replication, bacteriophages have evolved strategies to alter the metabolism of their bacterial host. SPO1 bacteriophage infection of Bacillus subtilis results in comprehensive remodeling of cellular processes, leading to conversion of the bacterial cell into a factory for phage progeny production. A cluster of 26 genes in the SPO1 genome, called the host takeover module, encodes for potentially cytotoxic proteins that spec… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 11 publications
(12 citation statements)
references
References 37 publications
0
12
0
Order By: Relevance
“…How ReoM and ReoY exert their effect on ClpCP is currently unknown, but a fascinating possibility would be a function similar to that of an adaptor protein to target a subset of protein substrates, including MurA, to the ClpCP complex for degradation. Several ClpC adaptors are known in B. subtilis (52, 53), but an adaptor for Bs MurAA is not among them (26, 52). Interestingly, the ClpC adaptor protein McsB from B. subtilis is also subject to phosphorylation like ReoM but, unlike ReoM, it targets its substrate CtsR to the ClpCP machinery only when phosphorylated (54).…”
Section: Discussionmentioning
confidence: 99%
“…How ReoM and ReoY exert their effect on ClpCP is currently unknown, but a fascinating possibility would be a function similar to that of an adaptor protein to target a subset of protein substrates, including MurA, to the ClpCP complex for degradation. Several ClpC adaptors are known in B. subtilis (52, 53), but an adaptor for Bs MurAA is not among them (26, 52). Interestingly, the ClpC adaptor protein McsB from B. subtilis is also subject to phosphorylation like ReoM but, unlike ReoM, it targets its substrate CtsR to the ClpCP machinery only when phosphorylated (54).…”
Section: Discussionmentioning
confidence: 99%
“…E. coli was grown on LB medium (1% tryptone, 1% NaCl, 0.5 g/l yeast extract). Pseudomonads were grown either on M9 mineral salt medium (Miller 1972), supplemented with 0.4% glucose as carbon source and 100 μM FeCl 3 to avoid iron limitation (this medium is referred to as M9 medium throughout this study), or on complex media. King's B medium was used for P. putida (2% peptone, 0.15% K 2 HPO 4 , 0.15% MgSO 4 × 7H 2 O, 1% glycerol), and LB medium was used for P. fluorescens or P. aeruginosa.…”
Section: Methodsmentioning
confidence: 99%
“…The kan R resistance cassette from pK18mobSacB (Schäfer et al 1994 ) was amplified using primers KanR-SspI-SD-F (5′-GCA TAA TAT TAC AGG ATG AGG ATC GTT TCG C-3′) and KanR-BsaI-R (5′-GCT AAC CGC GAG ACC TCA GAA GAA CTC GTC AAG AAG-3′), and the amp R resistance cassette of pUCP20-ANT1 was substituted by this kan R resistance cassette using SspI/BsaI for cloning, resulting in pUCP20-ANT2. For promoter reporter studies, gfp was PCR-amplified from pHT01- gfp (Mulvenna et al 2019 ) using SD-GFP-SpeI-F (5′-GCA GAC TAG TAA AGG AGG AAG GAT CCA TGA G-3′) and GFP-SbfI-R (5′-GCA GCC TGC AGG TTA TTT GTA TAG TTC ATC CAT GCC-3′); the fragment was digested with SpeI/SbfI, and cloned into the corresponding sites of pUCP20-ANT2 to generate pUCP20-ANT2- gfp . The multiple cloning site was amplified from pUCP20 using primers MCS-F (5′-GCC GAC TAG TAG GAG ATA TAC ATA TGG AAT TCG AGC TCG GTA CCC GGG GAT CCT C-3′) and MCS-R (5′-TGC CAA GCT TGC ATG CCT GC-3′); the PCR-fragment was digested with SpeI/SbfI, and cloned into the corresponding sites of pUCP20-ANT2 to obtain pUCP20-ANT2-MCS.…”
Section: Methodsmentioning
confidence: 99%
“…This a non-specific mechanism that SPO1 employs to target different bacterial transcription apparatus, regardless of the structural variations of RNA polymerases. This opens up the possibility for the generation of genetically modified SPO1 for the purpose of targeted gene therapy [ 84 , 85 ].…”
Section: Scientific Biotechnology Environmental and Medical Potential—a Short Notementioning
confidence: 99%